DBL™ Oxaliplatin for injection

国家: 新西兰

语言: 英文

来源: Medsafe (Medicines Safety Authority)

有效成分:

Oxaliplatin 50mg

可用日期:

Pfizer New Zealand Limited

INN（国际名称）:

Oxaliplatin 50 mg

剂量:

50 mg

药物剂型:

Powder for injection

组成:

Active: Oxaliplatin 50mg Excipient: Lactose monohydrate

每包单位数:

Vial, glass, Type I clear glass, 1 vial, 1 dose unit

类:

Prescription

处方类型:

Prescription

厂商:

Heraeus Deutschland GmbH & Co. KG

疗效迹象:

DBL™ Oxaliplatin, in combination with 5-fluorouracil and folinic acid, is indicated for: · Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of the primary tumour. · Treatment of advanced colorectal cancer.

產品總結:

Package - Contents - Shelf Life: Vial, glass, Type I clear glass, 1 vial - 1 dose units - 36 months from date of manufacture stored at or below 30°C. (below 30°C)

授权日期:

2009-01-09

产品特点

Version: pfdoxalv10520
Supersedes: pfdoxalvp10120
Page 1 of 25
NEW ZEALAND DATA SHEET
1.
PRODUCT NAME_ _
DBL
™
Oxaliplatin for Injection 20 mg Powder for injection
DBL
™
Oxaliplatin for Injection 50 mg Powder for injection
DBL
™
Oxaliplatin for Injection 100 mg Powder for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial of DBL Oxaliplatin for Injection (oxaliplatin powder for
injection) contains either
20 mg, 50 mg or 100 mg oxaliplatin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
DBL Oxaliplatin for Injection is a sterile lyophilised powder for
infusion.
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
DBL Oxaliplatin, in combination with 5-fluorouracil and folinic acid,
is indicated for:
•
Adjuvant treatment of stage III (Duke's C) colon cancer after complete
resection of the
primary tumour.
•
Treatment of advanced colorectal cancer.
4.2 DOSE AND METHOD OF ADMINISTRATION
DOSE
In combination with fluorouracil and folinic acid the recommended dose
for the treatment of
advanced colorectal cancer is either 85 mg/m
2
intravenously repeated every two weeks.
In combination with fluorouracil and folinic acid the recommended dose
for adjuvant
treatment is 85 mg/m
2
intravenously repeated every two weeks for 12 cycles (6 months).
DOSE ADJUSTMENTS
Prior to each treatment cycle, patients should be evaluated for
toxicity and the dose of
oxaliplatin adjusted accordingly.
Version: pfdoxalv10520
Supersedes: pfdoxalvp10120
Page 2 of 25
_NEUROLOGICAL TOXICITY _
If acute neurological reactions occur, e.g., acute pharyngolaryngeal
dysaesthesia, increase the
oxaliplatin infusion time from 2 hours to 6 hours. This decreases C
max
by 30% and may
lessen acute toxicities.
If sensory loss or paraesthesia persists longer than 7 days or
interferes with function (grade 2
toxicity), reduce oxaliplatin dose by 25%.
If sensory loss or paraesthesia interferes with activities of daily
living (grade 3 toxicity),
oxaliplatin should be discontinued.
_HAEMATOLOGICAL TOXICITY _
If haematologic